Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
ConclusionCompared with placebo, GLP-1 RAs may reduce the risk of MACE in patients with HF coexisting with T2DM, with a more significant efficiency of human GLP-1 RAs. More RCTs are needed to assess the cardiovascular benefits of GLP-1 RAs in HF, regardless of T2DM.RegistrationThe protocol for this meta-analysis is registered on PROSPERO [CRD42022357886].Graphical Abstract
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Heart Attack | Heart Failure | Stroke